Quidel

Quidel EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Quidel (QDEL) as of Oct 31, 2026 is -15.93 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -30.24 % — a change of -47.32% (higher).

EBIT/Assets

-15.93 %

YoY

-47.32%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Quidel is 2025 -15.93 % . Operating Income to Assets Ratio (EBIT/Assets) of Quidel was 2024 -30.24 % . It decreases by -47.32% higher compared to the previous year.

The Quidel EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
11.90 USD
Jan 1, 2019
10.18 USD
Jan 1, 2020
56.67 USD
Jan 1, 2021
37.28 USD
Jan 1, 2022
9.53 USD
Jan 1, 2023
1.62 USD
Jan 1, 2024
-30.24 USD
Jan 1, 2025
-15.93 USD
The Quidel EBIT/Assets history
YEAREBIT/AssetsYoY
-15.93 %-47.32%
-30.24 %-1,961.70%
1.62 %-82.95%
9.53 %-74.44%
37.28 %-34.22%
56.67 %+456.71%
10.18 %-14.44%
11.90 %+1,064.79%
1.02 %-189.33%
-1.14 %-269.75%
0.67 %-132.73%
-2.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quidel Stock analysis

What does Quidel do? Quidel Corporation is a US-based company specializing in the production of rapid tests for medical diagnostics. It was founded in 1979 and is headquartered in San Diego, California. Since 1991, it has been listed on the NASDAQ stock exchange. Quidel initially started as Diagnostic Reagents Laboratory (DRL) and focused on manufacturing diagnostic products for the veterinary sector. In 1990, it was renamed Quidel Corporation and expanded its operations into human diagnostics. The company's business model revolves around the development and production of immunological rapid tests that can quickly and easily diagnose infectious diseases and other health problems. Quidel focuses on creating high-quality, accurate, and cost-effective test procedures that can be used by healthcare professionals or even laypersons at home. One of Quidel's core competencies is bringing to market rapid tests that are easy to perform and provide immediate results without the need to send samples to a laboratory. The company offers a wide range of rapid tests for diagnosing various diseases. These include tests for infectious diseases such as influenza, streptococcus, Lyme disease, and chlamydia, as well as tests for pregnancy, drug abuse, and cardiovascular diseases. The tests are available as single tests or panel tests that can diagnose multiple diseases simultaneously. Quidel operates in four business segments: Molecular Diagnostics, Point-of-Care Diagnostics, Immunoassays, and Specialized Diagnostic Solutions. The Molecular Diagnostics segment focuses on developing molecular diagnostic tests and instruments for laboratory use. The Point-of-Care Diagnostics segment develops and produces rapid tests for use in medical practices and hospitals. The Immunoassays segment specializes in reagent-based tests for the quantitative analysis of biomolecules. The Specialized Diagnostic Solutions segment includes specialized diagnostic products, such as test systems for monitoring antibiotic therapies. In conclusion, Quidel Corporation specializes in the development and production of rapid tests for medical diagnostics. The company offers a wide range of high-quality, accurate, and cost-effective test procedures for diagnosing infectious diseases, pregnancy, drug abuse, and cardiovascular diseases. Quidel has gained a significant market share in the diagnostics field through its rapid tests and diverse range of test panels for various conditions, and it is known for its innovative products. Quidel is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quidel stock

Operating Income to Assets Ratio (EBIT/Assets) of Quidel is -15.93 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Quidel changed from -30.24 % to -15.93 %, representing a -47.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Quidel since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Quidel with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Quidel

All Key Metrics — Quidel